European standard clinical practice recommendations for newly diagnosed ependymoma of childhood and adolescence

<h2>Abstract</h2> Ependymomas are tumors of glial origin representing the second most common malignant brain tumors of childhood. Peak incidence in childhood is under 3 years of age. Most paediatric ependymomas arise intracranially and are molecularly divided into four groups, namely supratentorial ependymoma, ZFTA fusion-positive (ST-ZFTA), supratentorial ependymoma, YAP1 fusion-positive (ST-YAP1), posterior fossa group A (PF-A), and posterior fossa group B (PF-B) ependymoma. Spinal ependymomas in children are rare. An integrated diagnosis requires a combination of histological and molecular features as well as tumour localization. Staging with pre- and early post-surgery magnetic resonance imaging of the neuraxis, accompanied by cerebrospinal fluid (CSF) analysis 14 days post surgery must be performed. CSF at primary surgery is highly recommended to both detect and inform biomarkers. Patients should ideally be treated in specialized centers and, whenever possible, within a prospective clinical trial. Molecular classification has become increasingly important and will be applied to enable patient stratification in upcoming clinical trials. However, there are not yet specific treatment recommendations for distinct molecular groups. Apart from the molecular group, the extent of neurosurgical resection is the most consistent prognostic factor. Therefore, the feasibility of second-look surgery targeting complete resection should always be evaluated if residual disease. Adjuvant radiotherapy has been shown to be effective in consolidating local control and is therefore recommended following complete resection. Focal radiotherapy is the standard of care for patients with non-disseminated ependymoma, and craniospinal radiotherapy is recommended in older children with metastatic disease. For very young children with metastatic disease, radiotherapy avoidance strategies using systemic therapy is recommended to reduce the risk of neurocognitive effects. Highly conformal techniques such as proton beam therapy or intensity-modulated radiation therapy are preferred. Chemotherapy bridging therapy may be applied until patients reach 12–18 months of age, or to facilitate complete resections where further surgery is planned.

Authors

Institutions

Publication Details

Journal
EJC Paediatric Oncology
Published
2025-04-09
DOI
https://doi.org/10.1016/j.ejcped.2025.100227
Citations
3
Primary Topic
Glioma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
4.88

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

European standard clinical practice recommendations for newly diagnosed ependymoma of childhood and adolescence

Marie‐Lise C. van Veelen, Kristian W. Pajtler, Martin U. Schuhmann, Stefan Rutkowski et al.
3 citations
EJC Paediatric Oncology
Glioma Diagnosis and Treatment
4.88
article

European standard clinical practice recommendations for newly diagnosed ependymoma of childhood and adolescence

Marie‐Lise C. van Veelen, Kristian W. Pajtler, Martin U. Schuhmann, Stefan Rutkowski, Martin Benesch, Nicky Thorp, Stéphanie Bolle, Timothy A. Ritzmann, Denise Obrecht, John‐Paul Kilday, Ulrich‐Wilhelm Thomale, Richard Guy Grundy, Ulrich Schüller, Alba Rubio San Simon, Geraldina Poggi, Stephan Tippelt, Ana Fernández‐Teijeiro, Maura Massimino, Pierre Leblond, Beate Timmermann
article en
3 citations

Abstract

<h2>Abstract</h2> Ependymomas are tumors of glial origin representing the second most common malignant brain tumors of childhood. Peak incidence in childhood is under 3 years of age. Most paediatric ependymomas arise intracranially and are molecularly divided into four groups, namely supratentorial ependymoma, ZFTA fusion-positive (ST-ZFTA), supratentorial ependymoma, YAP1 fusion-positive (ST-YAP1), posterior fossa group A (PF-A), and posterior fossa group B (PF-B) ependymoma. Spinal ependymomas in children are rare. An integrated diagnosis requires a combination of histological and molecular features as well as tumour localization. Staging with pre- and early post-surgery magnetic resonance imaging of the neuraxis, accompanied by cerebrospinal fluid (CSF) analysis 14 days post surgery must be performed. CSF at primary surgery is highly recommended to both detect and inform biomarkers. Patients should ideally be treated in specialized centers and, whenever possible, within a prospective clinical trial. Molecular classification has become increasingly important and will be applied to enable patient stratification in upcoming clinical trials. However, there are not yet specific treatment recommendations for distinct molecular groups. Apart from the molecular group, the extent of neurosurgical resection is the most consistent prognostic factor. Therefore, the feasibility of second-look surgery targeting complete resection should always be evaluated if residual disease. Adjuvant radiotherapy has been shown to be effective in consolidating local control and is therefore recommended following complete resection. Focal radiotherapy is the standard of care for patients with non-disseminated ependymoma, and craniospinal radiotherapy is recommended in older children with metastatic disease. For very young children with metastatic disease, radiotherapy avoidance strategies using systemic therapy is recommended to reduce the risk of neurocognitive effects. Highly conformal techniques such as proton beam therapy or intensity-modulated radiation therapy are preferred. Chemotherapy bridging therapy may be applied until patients reach 12–18 months of age, or to facilitate complete resections where further surgery is planned.

EJC Paediatric OncologyVol. 5
Nottingham University Hospitals NHS Trust (GB), Universität Hamburg (DE), German Cancer Research Center (DE), Medical University of Graz (AT), Heidelberg University (DE), Université Paris-Saclay (FR), Institut Gustave Roussy (FR), University Hospital Heidelberg (DE), Clatterbridge Cancer Centre NHS Foundation Trust (GB), University of Manchester (GB), Hospital Universitario Virgen Macarena (ES), Brain Tumour Research (GB), Centre Léon Bérard (FR), University Medical Center Hamburg-Eppendorf (DE), Kinderkrebs-Zentrum Hamburg (DE), National Center for Tumor Diseases (DE), Hospital Infantil Universitario Niño Jesús (ES), Hopp Children's Cancer Center Heidelberg (DE), Essen University Hospital (DE), Centre de Recherche en Cancérologie de Lyon (FR), University Children's Hospital Tübingen (DE), Cancer Research UK Manchester Institute (GB), The Christie Hospital (GB), Erasmus MC Cancer Institute (NL), IRCCS Eugenio Medea (IT), Fondazione IRCCS Istituto Nazionale dei Tumori (IT), Royal Manchester Children's Hospital (GB), West German Heart and Vascular Center Essen (DE), Charité - Universitätsmedizin Berlin (DE), University of Tübingen (DE)
CERN, Deutsche Forschungsgemeinschaft, Fondazione Regionale per la Ricerca Biomedica
Openalex Percentile: Top 6%
Glioma Diagnosis and Treatment
4.88
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.